ALTO-300 was significantly more effective in major depressive disorder patients with a specific EEG biomarker than in those without, according to results from an Alto Neuroscience Phase IIa study.
Tag Archive for: major depressive disorder
Today the company said its experimental drug to treat major depressive disorder (MDD) had failed to significantly reduce the severity of the condition in a mid-stage study.
According to Sage Therapeutics, U.S. wholesalers are expected to pay almost $16,000 for the full 14-day treatment.
After several rejections over 20-plus years, Fabre-Kramer Pharmaceuticals has secured the FDA’s approval for its major depressive disorder drug gepirone hydrochloride, now marketed under the brand name Exxua.
Following promising results in major depressive disorder, Alto Neuroscience on Tuesday reported positive data for its investigational drug ALTO-100 in post-traumatic stress disorder.
Navacaprant showed statistically significant and clinically meaningful improvements along scales that measure symptoms of depression and anhedonia – a feature of MDD that impairs the capacity to experience or anticipate pleasure – in patients, Neumora said.
Intra-Cellular Therapies’ Caplyta (lumateperone) met its primary endpoint in its Phase III trial, easing the burden of depressive episodes in patients with major depressive disorder (MDD) or bipolar depression with mixed features.
A biotech company focused on short-duration psychedelic-assisted therapies for mental health conditions announced positive top-line results from the first placebo-controlled efficacy study exploring a short-duration psychedelic for the treatment of major depressive disorder.
In a fireside chat at the 41st J.P. Morgan Healthcare Conference in San Francisco, CEO Rick Gonzalez said AbbVie is well-positioned for continued growth.
Among updates from several pharma companies, Sanofi CEO Paul Hudson presented the company’s outlook for the new year, highlighting upcoming milestones and achievements that mark what he called the “new Sanofi.”
